Affinity DataKi: 3.70E+3nMAssay Description:Inhibition of recombinant KRAS G12C mutant (unknown origin) assessed as rate of inactivation by LC-MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 0.900nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 0.900nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western methodMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western methodMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair